Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

What makes Recursion Pharmaceuticals (RXRX) so attractive

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, ...

Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its first AI enabled clinical proof of concept in familial adenomatous polyposis. The company advances five clinical programs, signaling broader use ...

BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America ...

Can This AI Stock Bounce Back in 2026?

Artificial intelligence (AI) is all the rage on Wall Street these days, but not every AI stock is equally successful. Some of ...
Seeking Alpha

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered ...

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
The Motley Fool

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum

Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Recursion Pharmaceuticals, Inc. (RXRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

It's good to see everybody, and welcome back to TD Cowen's 46th Annual Healthcare Conference. It is my pleasure to be joined today by Recursion's CFO, Ben Taylor. We've got a lot of great stuff to ...
The Motley Fool

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...
Benzinga.com

What's Going On With Recursion Pharmaceuticals Stock?

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...